
    
      This is Versi Retriever mechanical thrombectomy device approving study in Japan. Multi
      center, single arm, prospective registry trial. Physicians control trial, conducted my N
      Sakai, Kobe City Medical Center General Hospital.

      60 cases will be enrolled and 90 days follow up need. Primary endpoint is favorable clinical
      outcome, mRS 0-2. Secondary endpoint are mortality in 90days, immediate successful
      recanalization, TICI 2b-3, symptomatic intracranial hemorrhage, and any adverse event related
      to device and or procedure.
    
  